Efficacy of interleukin-17 inhibitors in psoriasis patients: a comparative non-randomized study
Background. IL-17 blockers have expanded the possibilities of psoriasis therapy. Their high efficacy and safety profile have been demonstrated in phase I–III studies and in real-world clinical practice. No direct comparative studies of the efficacy of drugs of this class registered in the Russian Fe...
Saved in:
Main Authors: | Arfenya E. Karamova, Anastasiia A. Vorontsova, Olga G. Artamonova |
---|---|
Format: | Article |
Language: | English |
Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2025-06-01
|
Series: | Vestnik Dermatologii i Venerologii |
Subjects: | |
Online Access: | https://vestnikdv.ru/jour/article/viewFile/16872/pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
by: Т. V. Korotaeva
Published: (2021-04-01) -
INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01) -
Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study
by: T. V. Korotaeva, et al.
Published: (2020-11-01) -
Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2021-03-01) -
The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy
by: E. L. Nasonov, et al.
Published: (2024-12-01)